Fig. 2

Kaplan-Meier curves for progression-free survival (PFS) of patients with metastatic MITF family translocation renal cell carcinoma treated with (a) a tyrosine kinase inhibitor (TKI) or (b) an immune checkpoint inhibitor (ICI)